Email |

King Pharmaceuticals reports 8% second quarter total revenues increase

Published August 9th, 2006 | 0 Comments

King Pharmaceuticals, Inc. announced today that total revenues increased 8% to $500 million during the second quarter ended June 30, 2006, compared to $463 million in the second quarter of 2005.

Including special items, net earnings increased to $111 million and diluted earnings per share increased to $0.46 during the second quarter ended June 30, 2006, compared to net income of $20 million and diluted earnings per share of $0.08 in the same period of the prior year. Excluding special items, net earnings increased to $112 million and diluted earnings per share increased to $0.46 during the second quarter ended June 30, 2006, compared to net earnings of $107 million and diluted earnings per share of $0.44 in the second quarter of 2005.

Net revenue from branded pharmaceuticals totaled $419 million for the second quarter of 2006, a 5% increase from $400 million during the second quarter of 2005. This increase was primarily due to price increases taken in the second half of 2005.

Altace(R) net sales totaled $154 million during the second quarter of 2006, an increase of 7% from $144 million during the second quarter of 2005.

Net sales of Skelaxin(R) (metaxalone) totaled $97 million during the second quarter of 2006, an increase of 12% compared to $87 million during the same period of the prior year.

Thrombin-JMI(R) (thrombin, topical, bovine, USP) net sales totaled $62 million during the second quarter of 2006, a 17% increase from $53 million during the second quarter of 2005.

Net sales of Sonata(R) (zaleplon) totaled $24 million during the second quarter of 2006, an increase of 24% compared to $19 million during the second quarter of the prior year.

Levoxyl(R) (levothyroxine sodium tablets, USP) net sales totaled $29 million during the second quarter ended June 30, 2006, a decrease of 30% from $41 million during the second quarter of 2005.

King's Meridian Medical Technologies business contributed revenue totaling $54 million during the second quarter of 2006, an increase of 52% from $35 million during the same period of the prior year. As the Company has previously disclosed, revenue from Meridian may fluctuate significantly from quarter-to-quarter as buying patterns of government and commercial customers vary. Accordingly, the Company expects Meridian revenue to be significantly lower in second half of 2006 compared to the first half of 2006.

Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $21 million during the second quarter ended June 30, 2006, compared to $20 million during the second quarter of 2005. During the second quarter ended June 30, 2006, net revenue from contract manufacturing equaled $6 million.

As of June 30, 2006, the company's cash and cash equivalents and investments in debt securities totaled approximately $803 million.

Joseph Squicciarino, King's chief financial officer, said "King generated strong cash flow from operations of $176 million during the second quarter of 2006. We plan to utilize our cash position to fuel our business development initiatives and aggressively invest in the further development of products in our pipeline. Accordingly, we expect to continue increasing our R&D investment in each of the remaining quarters of this year, as our total investment for the full year of 2006 could exceed $150 million."

Discuss This Story

Be the first to comment: Sign In or Create Profile .

To comment, you must register.

Comments are the sole responsibility of the registered user participating in online discussions. You agree not to post comments off topic, abusive, obscene, defamatory, vulgar, threatening or an invasion of privacy. Violators may be banned.

Click here to review our complete user agreement.